AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39602143 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 390
Study 39602157 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3974
Study 39602157 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3974
Study 39602173 — intervention group
Group type: EXPERIMENTAL
Intervention: T-TEER + OMT
Number of subjects: 300
Study 39602173 — intervention group
Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 300
Study 39602203 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based routine process monitoring and feedback system
Number of subjects: 475
Study 39602203 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 475
Study 39602207 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory strength training
Number of subjects: 80
Study 39602207 — intervention group
Group type: COMPARATOR
Intervention: Respiratory relaxation training
Number of subjects: 80
Study 39602215 — intervention group
Group type: EXPERIMENTAL
Intervention: CogXergaming (n=13)
Number of subjects: 27
Study 39602215 — intervention group
Group type: COMPARATOR
Intervention: Matter of Balance (MOB) (n=14)
Number of subjects: 27
Study 39602218 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning course
Number of subjects: 350
Study 39602218 — intervention group
Group type: COMPARATOR
Intervention: Synchronous course (Control)
Number of subjects: 350
Study 39602341 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy (ARI0002h; academic BCMA-targeted CAR T-cell therapy)
Number of subjects: 63
Study 39602341 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET/CT response assessed on day 100
Number of subjects: 63
Study 39602341 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline [18F]FDG-PET/CT with a metabolic tumor volume (MTV) of 25 or more
Number of subjects: 63
Study 39602341 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with extramedullary plasmacytomas (EMD)
Number of subjects: 63
Study 39602341 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET/CT
Number of subjects: 63
Study 39602341 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) and progression-free survival (PFS)
Number of subjects: 63
Study 39602342 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan-based regimen (BU/THIO/FLU)
Number of subjects: 308
Study 39602342 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan-based regimen (TREO/THIO/FLU)
Number of subjects: 308
Study 39602397 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavored cigarillo packaging
Number of subjects: 89
Study 39602397 — intervention group
Group type: COMPARATOR
Intervention: Unflavored cigarillo packaging
Number of subjects: 89
Study 39602441 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted telemedicine HCV treatment (TeleHCV)
Number of subjects: 203
Study 39602441 — intervention group
Group type: COMPARATOR
Intervention: Peer-assisted referral to local providers (enhanced usual care; EUC)
Number of subjects: 203
Study 39602439 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health education intervention (HEI) led by women's groups
Number of subjects: 1070
Study 39602479 — intervention group
Group type: EXPERIMENTAL
Intervention: MIC spray mixed with 6 mg aspirin + placebo tablet (Treatment 1)
Number of subjects: 157
Study 39602479 — intervention group
Group type: EXPERIMENTAL
Intervention: MIC spray mixed with 6 mg wintergreen oil + placebo tablet (Treatment 2)
Number of subjects: 157
Study 39602479 — intervention group
Group type: EXPERIMENTAL
Intervention: MIC spray mixed with 6 mg wintergreen oil + 325 mg aspirin tablet (Treatment 3)
Number of subjects: 157
Study 39602479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 39602624 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lenacapavir every 26 weeks
Number of subjects: 3265
Study 39602624 — intervention group
Group type: COMPARATOR
Intervention: Daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF)
Number of subjects: 3265
Study 39602624 — intervention group
Group type: COMPARATOR
Intervention: Background HIV incidence in the screened population
Number of subjects: 3265
Study 39602624 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lenacapavir
Number of subjects: 3265
Study 39602629 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 primary dose and 1 booster dose of PCV10 (1p+1)
Number of subjects: 1363
Study 39602629 — intervention group
Group type: COMPARATOR
Intervention: 2 primary doses and 1 booster dose of PCV10 (2p+1)
Number of subjects: 1363
Study 39602629 — intervention group
Group type: COMPARATOR
Intervention: 3 primary doses of PCV10 (3p+0)
Number of subjects: 1363
Study 39602629 — intervention group
Group type: COMPARATOR
Intervention: 0 primary doses and 1 booster dose of PCV10 (0p+1)
Number of subjects: 1363
Study 39602630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 303
Study 39602630 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 303
Study 39602653 — intervention group
Group type: EXPERIMENTAL
Intervention: Obecabtagene autoleucel (obe-cel)
Number of subjects: 153
Study 39602790 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration (CWI)
Number of subjects: 134
Study 39602790 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 134
Study 39603331 — intervention group
Group type: EXPERIMENTAL
Intervention: True Definition® intraoral scanner
Number of subjects: 36
Study 39603384 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab for prophylaxis of acute graft vs host disease (aGvHD) after allo-HSCT
Number of subjects: 0
Study 39603580 — intervention group
Group type: EXPERIMENTAL
Intervention: abbreviated DASI (aDASI)
Number of subjects: 0
Study 39603580 — intervention group
Group type: COMPARATOR
Intervention: original DASI
Number of subjects: 0
Study 39603709 — intervention group
Group type: EXPERIMENTAL
Intervention: ivarmacitinib 4 mg
Number of subjects: 566
Study 39603709 — intervention group
Group type: EXPERIMENTAL
Intervention: ivarmacitinib 8 mg
Number of subjects: 566
Study 39603709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study 39603709 — intervention group
Group type: EXPERIMENTAL
Intervention: ivarmacitinib 4 mg and 8 mg
Number of subjects: 566
Study 39603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing any revascularization procedure (68.5%; 1,184/1,729)
Number of subjects: 1729
Study 39603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1729
Study 39603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 1729
Study 39603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 1729
Study 39603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral vessel disease
Number of subjects: 1729
Study 39603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced left ventricular ejection fraction
Number of subjects: 1729
Study 39603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute indication for the index coronary angiography
Number of subjects: 1729
Study 39603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of coronary vessels presenting severe stenosis
Number of subjects: 1729
Study 39603781 — intervention group
Group type: EXPERIMENTAL
Intervention: Local aneurysm complications
Number of subjects: 1729
Study 39603779 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated antiplatelet therapy (APT) for 1 month
Number of subjects: 4579
Study 39603779 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet therapy (APT) for ≥3 months
Number of subjects: 4579
Study 39603779 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated APT
Number of subjects: 4579
Study 39603779 — intervention group
Group type: COMPARATOR
Intervention: Standard APT
Number of subjects: 4579
Study 39604073 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle mass (SMM) sharp-falling trajectory
Number of subjects: 411
Study 39604073 — intervention group
Group type: EXPERIMENTAL
Intervention: Total adipose tissue area (TATA) sharp-falling trajectory
Number of subjects: 411
Study 39604073 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractory cachexia (SMM and TATA sharp-falling)
Number of subjects: 411
Study 39604073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cachexia (SMM or TATA sharp-falling)
Number of subjects: 411
Study 39604073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cachexia (SMM and TATA stable)
Number of subjects: 411
Study 39604073 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3-4 adverse events
Number of subjects: 411
Study 39604382 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery training along with traditional physical therapy program
Number of subjects: 50
Study 39604382 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy program
Number of subjects: 50
Study 39604766 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrographic flow (EGF) mapping during atrial fibrillation (AF)
Number of subjects: 10
Study 39604766 — intervention group
Group type: COMPARATOR
Intervention: Electrographic flow (EGF) mapping during sinus rhythm (SR)
Number of subjects: 10
Study 39604766 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrographic flow consistency (EGFC) during AF
Number of subjects: 10
Study 39604766 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrographic flow consistency (EGFC) correlation with bipolar voltage
Number of subjects: 10
Study 39604779 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral betamethasone (BTM) at 0.3 mg/kg/day for 3 days, 0.15 mg/kg/day for 2 days, and 0.05 mg/kg/day on the last day
Number of subjects: 51
Study 39604779 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral betamethasone (BTM)
Number of subjects: 51
Study 39604844 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anesthesia evaluation
Number of subjects: 1117
Study 39604863 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVKA-II
Number of subjects: 141
Study 39604863 — intervention group
Group type: EXPERIMENTAL
Intervention: dp-ucMGP
Number of subjects: 141
Study 39604863 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Agatston score
Number of subjects: 141
Study 39604913 — intervention group
Group type: EXPERIMENTAL
Intervention: ColonAiQ assay
Number of subjects: 105285
Study 39604941 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel crowns (n=10)
Number of subjects: 40
Study 39604941 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated commercially available zirconia crowns (NuSmile) (n=10)
Number of subjects: 40
Study 39604941 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM zirconia crowns (n=10)
Number of subjects: 40
Study 39604941 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM hybrid crowns (n=10)
Number of subjects: 40
Study 39604957 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine at a dose of 25 mg/m2
Number of subjects: 22
Study 39604957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 22
Study 39605008 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g resistant potato starch (RPS)
Number of subjects: 70
Study 39605008 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g resistant potato starch (RPS)
Number of subjects: 70
Study 39605008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 39605014 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic carvedilol (Arm B)
Number of subjects: 110
Study 39605014 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Arm C)
Number of subjects: 110
Study 39605055 — intervention group
Group type: EXPERIMENTAL
Intervention: NavCare-EU intervention plus standard care
Number of subjects: 246
Study 39605055 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 246
Study 39605077 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 ml total bacterial count fecal microbiota transplantation
Number of subjects: 100
Study 39605077 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml total bacterial count fecal microbiota transplantation
Number of subjects: 100
Study 39605293 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Combined with Cognitive Intervention Therapy
Number of subjects: 0
Study 39605293 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39605874 — intervention group
Group type: EXPERIMENTAL
Intervention: Elamipretide 40 mg daily subcutaneous administration for 48 weeks followed by a 4-week follow-up period.
Number of subjects: 176
Study 39605874 — intervention group
Group type: COMPARATOR
Intervention: Placebo group.
Number of subjects: 176
Study 39606217 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 79
Study 39606217 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 79
Study 39606218 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nudge letters
Number of subjects: 299881
Study 39606218 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no electronic letter)
Number of subjects: 299881
Study 39606219 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX regimen chemotherapy (S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2) combined with tislelizumab and low-dose radiation therapy (LDRT)
Number of subjects: 49
Study 39606360 — intervention group
Group type: EXPERIMENTAL
Intervention: CXR-Lung-Risk + TargetCOPD
Number of subjects: 27648
Study 39606360 — intervention group
Group type: COMPARATOR
Intervention: TargetCOPD alone
Number of subjects: 27648
Study 39606360 — intervention group
Group type: COMPARATOR
Intervention: TargetCOPD
Number of subjects: 27648
Study 39606360 — intervention group
Group type: EXPERIMENTAL
Intervention: CXR-Lung-Risk
Number of subjects: 27648
Study 39606374 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-activity behavioral intervention (SAM)
Number of subjects: 190
Study 39606374 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (FAST+SAM)
Number of subjects: 190
Study 39606379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit® Charge 3 device and custom mood-reporting app with positive psychology-based activities (Roadmap)
Number of subjects: 166
Study 39606379 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 166
Study 39606414 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (NADT)
Number of subjects: 37
Study 39606414 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-CMB model
Number of subjects: 37
Study 39606414 — intervention group
Group type: COMPARATOR
Intervention: mTOR inhibitors
Number of subjects: 37
Study 39606581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrologist intervention
Number of subjects: 380
Study 39606581 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 380
Study 39606707 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial rehabilitation therapy (personalized program based on one of three rehabilitation treatment modules: graded activity, exposure)
Number of subjects: 10
Study 39606837 — intervention group
Group type: EXPERIMENTAL
Intervention: Galinpepimut-S (WT1 peptide vaccine)
Number of subjects: 0
Study 39606837 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 0
Study 39606906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat + Azacitidine + Venetoclax
Number of subjects: 0
Study 39606939 — intervention group
Group type: COMPARATOR
Intervention: Resistance training during anticancer therapy
Number of subjects: 2221
Study 39606939 — intervention group
Group type: COMPARATOR
Intervention: Resistance training after anticancer therapy
Number of subjects: 2221
Study 39606939 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 2221
Study 39607014 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam
Number of subjects: 3339
Study 39607286 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over ipsilesional occipital cortex
Number of subjects: 18
Study 39607286 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over ipsilesional parietal cortex
Number of subjects: 18
Study 39607286 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 18
Study 39607474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin 0.1%
Number of subjects: 1162
Study 39607474 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1162
Study 39607505 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol
Number of subjects: 125
Study 39607652 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation exposure treatment
Number of subjects: 30
Study 39607652 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitting analysis of decay pattern of EDR values
Number of subjects: 30
Study 39607729 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m)
Number of subjects: 21
Study 39607729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 39607729 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 21
Study 39608001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Treatment Education Program (STEP-1)
Number of subjects: 70
Study 39608001 — intervention group
Group type: COMPARATOR
Intervention: Control condition (relaxation education)
Number of subjects: 70
Study 39608000 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOPE (internet-delivered psychoeducation)
Number of subjects: 141
Study 39608000 — intervention group
Group type: COMPARATOR
Intervention: Active control (web-based self-study)
Number of subjects: 141
Study 39608000 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 141
Study 39608305 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance with 5-FU/leucovorin (LV)-A after induction with FOLFIRI-aflibercept (arm A)
Number of subjects: 170
Study 39608305 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI-aflibercept until progression (arm B)
Number of subjects: 170
Study 39608305 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for arm A
Number of subjects: 170
Study 39608305 — intervention group
Group type: COMPARATOR
Intervention: Overall survival for arm B
Number of subjects: 170
Study 39608381 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonists
Number of subjects: 85373
Study 39608381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85373
Study 39608389 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 plus SIIV4
Number of subjects: 3322
Study 39608389 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1345 plus placebo
Number of subjects: 3322
Study 39608389 — intervention group
Group type: COMPARATOR
Intervention: SIIV4 plus placebo
Number of subjects: 3322
Study 39608389 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 plus mRNA-1273.214
Number of subjects: 3322
Study 39608389 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273.214 plus placebo
Number of subjects: 3322
Study 39608453 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispecific T-cell engagers (BiTEs)
Number of subjects: 71
Study 39608453 — intervention group
Group type: COMPARATOR
Intervention: Non-B-cell mutation antigen (BCMA)-targeted BiTEs
Number of subjects: 71
Study 39608453 — intervention group
Group type: COMPARATOR
Intervention: Non-BCMA-targeted BiTEs
Number of subjects: 71
Study 39608590 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiffening wire
Number of subjects: 54
Study 39608590 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 39608608 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-AF maize and groundnut flours provided monthly to the intervention group.
Number of subjects: 2842
Study 39608608 — intervention group
Group type: COMPARATOR
Intervention: Skin lotion distributed monthly to the control group.
Number of subjects: 2842
Study 39608608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received infant and young child feeding education equally.
Number of subjects: 2842
Study 39608824 — intervention group
Group type: EXPERIMENTAL
Intervention: Four Square Step Test (FSST)
Number of subjects: 37
Study 39608824 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice Stepping Reaction Time Test (CSRTT)
Number of subjects: 37
Study 39608824 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Step Length Test (MSLT)
Number of subjects: 37
Study 39608824 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Step Test (AST)
Number of subjects: 37
Study 39608861 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 41
Study 39608861 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with persistent AF with preserved LVEF)
Number of subjects: 41
Study 39608864 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative imaging analysis (QIA) of high-resolution chest CT
Number of subjects: 20
Study 39608864 — intervention group
Group type: EXPERIMENTAL
Intervention: QIA scores
Number of subjects: 20
Study 39608975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (3 mg/kg for body weight <60 kg; 200 mg for ≥60 kg) every 3 weeks until 24 months or 35 cycles and 3 doses of the HPV quadrivalent vaccine (initial dose prior to sintilimab initiation, with subsequent doses at 2 and 6 months)
Number of subjects: 13
Study 39608979 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus carboplatin and pemetrexed
Number of subjects: 412
Study 39608979 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and pemetrexed
Number of subjects: 412
Study 39608979 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (after 2 years)
Number of subjects: 412
Study 39608979 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (among responders)
Number of subjects: 412
Study 39608989 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional rituximab injection
Number of subjects: 108
Study 39608989 — intervention group
Group type: COMPARATOR
Intervention: Involved site radiation therapy (ISRT)
Number of subjects: 108
Study 39608989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 108